Illumina - ILMN Stock Forecast, Price & News

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Analysts Set New Price Targets

ILMN has been the topic of several research analyst reports. Stifel Nicolaus lowered their price objective on Illumina from $480.00 to $300.00 and set a "buy" rating on the stock in a research report on Friday, August 12th. Morgan Stanley dropped their target price on Illumina from $350.00 to $240.00 and set an "equal weight" rating for the company in a research report on Friday, August 12th. Cowen decreased their price target on shares of Illumina from $506.00 to $492.00 in a research note on Friday, May 6th. UBS Group dropped their price objective on shares of Illumina from $350.00 to $245.00 and set a "neutral" rating on the stock in a research note on Wednesday. Finally, Barclays decreased their price target on Illumina to $130.00 in a research note on Monday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, Illumina currently has an average rating of "Hold" and an average price target of $259.21.

Illumina Trading Down 3.0 %

NASDAQ:ILMN opened at $219.83 on Wednesday. The company's fifty day simple moving average is $201.67 and its 200-day simple moving average is $272.28. The company has a current ratio of 1.00, a quick ratio of 0.82 and a debt-to-equity ratio of 0.05. The stock has a market cap of $34.54 billion, a P/E ratio of -3,663.22, a PEG ratio of 2.62 and a beta of 1.15. Illumina has a 52 week low of $173.45 and a 52 week high of $525.00.

Illumina (NASDAQ:ILMN - Get Rating) last released its quarterly earnings data on Thursday, August 11th. The life sciences company reported $0.57 EPS for the quarter, missing analysts' consensus estimates of $0.63 by ($0.06). The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.22 billion. Illumina had a positive return on equity of 5.61% and a negative net margin of 0.43%. The business's revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.87 EPS. Equities research analysts predict that Illumina will post 2.78 EPS for the current fiscal year.

Insider Transactions at Illumina

In related news, SVP Alexander Aravanis sold 539 shares of the firm's stock in a transaction that occurred on Thursday, July 7th. The shares were sold at an average price of $200.00, for a total transaction of $107,800.00. Following the completion of the sale, the senior vice president now directly owns 3,346 shares in the company, valued at $669,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, SVP Alexander Aravanis sold 539 shares of the business's stock in a transaction on Thursday, July 7th. The shares were sold at an average price of $200.00, for a total transaction of $107,800.00. Following the transaction, the senior vice president now directly owns 3,346 shares in the company, valued at approximately $669,200. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Susan H. Tousi sold 250 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $214.85, for a total transaction of $53,712.50. Following the transaction, the senior vice president now owns 41,833 shares in the company, valued at approximately $8,987,820.05. The disclosure for this sale can be found here. Company insiders own 0.13% of the company's stock.